Seelos Therapeutics Announces Final Data from Phase I PK/PD Study of Intranasal Racemic Ketamine (SLS-002) and Clinical Development Plans
Stock Information for Seelos Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.